CHEST guideline updates support minimally invasive resection and targeted therapy to enhance survival in Stage I–II NSCLC.

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80% of all lung ...

ROS1 基因（全称：c-ROS 肉瘤致癌因子-受体酪氨酸激酶），与 EGFR、ALK 均为非小细胞肺癌（NSCLC）明确的驱动基因，属于酪氨酸激酶胰岛素受体基因[1]。今天「 丁香园肿瘤时间 」和大家一起学习了解 ROS1 ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

近年来，免疫治疗在非小细胞肺癌（NSCLC）围术期治疗领域取得突破性进展，围术期免疫联合化疗新辅助 + 辅助治疗已成为可手术 II - III 期 NSCLC 的新标准。在刚刚结束的 2025 ...

When non-small cell lung cancer (NSCLC) spreads beyond the lungs, it often metastasizes to the bones. Estimates suggest 20 to 30 percent of people with NSCLC have bone metastases at the time of ...

DNMT3A mutations emerged as potential biomarkers for enhanced immunotherapy benefit in non-small cell lung cancer.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...

近年来，肺癌围术期免疫治疗取得了突破性进展，成为非小细胞肺癌（NSCLC）全程管理中的重要环节。在刚刚结束的 2025 年美国临床肿瘤学会（ASCO）年会上，多项围术期治疗相关研究数据重磅公布，其中基于 AEGEAN 研究的术后分子残留病灶状态与新辅助 ctDNA 动态、基因组突变及临床结局的关联数据结果以口头汇报形式重磅公布，为围术期免疫治疗获益人群的筛选提供了重要循证医学依据。

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most ...